Randomized pahse III study evaluating the efficacy of hepatic arterial infusion chemotherapy for metastatic colorectal cancer patients with unresectable liver metastases

INTERVENTION: In the tested group, after the radiological placement of port and catheter system, hepatic arterial infusion using 5FU is performed within 6 months at the longest, and then FOLFOX+Bevacizumab therapy is performed. In the control group, FOLFOX+Bevacizumab therapy is performed. CONDITION: Colorectal cancer PRIMARY OUTCOME: Overall survival period SECONDARY OUTCOME: Adverse events; Time to treatment failure INCLUSION CRITERIA: 1)pathologically confirmed colorectal cancer 2)ALP more than 600 IU/L and unresectable liver metastases 3)No prior treatment using L‐OHP or Bevacizumab 4)20 years old or more 5)Performance status (ECOG):0‐2 6)No mtter of measurable lesion 7)Previous chemotherapy as folloes; ‐ No prior chemotherapy ‐ Chemotherapy of fluoropyrimidines for less than 2 weeks ‐ Previous adjuvant chemotherapy of fluoropyrimidines with more than 6 months interval to the recurrence, and no previous chemotherapy to the recurrence 8)Within normal function of major organs 9)More than 8 weeks survival expected 10)Written informed consent